Victory Capital Management Inc. decreased its position in Artivion, Inc. (NYSE:AORT – Free Report) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 105,769 shares of the company’s stock after selling 1,430 shares during the period. Victory Capital Management Inc.’s holdings in Artivion were worth $3,024,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in AORT. Lord Abbett & CO. LLC purchased a new stake in shares of Artivion in the third quarter valued at about $5,798,000. Tidal Investments LLC boosted its holdings in shares of Artivion by 602.2% in the third quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock valued at $4,179,000 after acquiring an additional 134,642 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Artivion by 58.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after acquiring an additional 125,668 shares in the last quarter. Sio Capital Management LLC purchased a new stake in shares of Artivion in the third quarter valued at about $3,226,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Artivion by 394.9% in the third quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock valued at $2,606,000 after purchasing an additional 78,120 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.
Artivion Stock Performance
Shares of AORT opened at $24.15 on Monday. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The stock has a market cap of $1.02 billion, a P/E ratio of -1,207.25 and a beta of 1.79. The company has a 50-day moving average of $28.66 and a two-hundred day moving average of $27.74. Artivion, Inc. has a 12-month low of $19.36 and a 12-month high of $32.33.
Wall Street Analyst Weigh In
Several analysts recently commented on AORT shares. Stifel Nicolaus reduced their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, February 25th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Finally, Needham & Company LLC reduced their price objective on shares of Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $31.40.
Check Out Our Latest Research Report on Artivion
Insiders Place Their Bets
In other news, SVP Jean F. Holloway sold 18,020 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $425,452.20. Following the completion of the transaction, the senior vice president now owns 197,184 shares of the company’s stock, valued at $4,655,514.24. The trade was a 8.37 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John E. Davis sold 15,100 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total transaction of $356,511.00. Following the completion of the transaction, the insider now directly owns 208,778 shares of the company’s stock, valued at approximately $4,929,248.58. This represents a 6.74 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 90,799 shares of company stock worth $2,356,223. Insiders own 8.10% of the company’s stock.
Artivion Company Profile
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Featured Stories
- Five stocks we like better than Artivion
- Consumer Staples Stocks, Explained
- How to Build the Ultimate Everything ETF Portfolio
- 5 discounted opportunities for dividend growth investors
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORT – Free Report).
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.